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Abstract 
Background: Human Fas ligand extracellular domain has been investigated as an important target protein in the 
field of medical biotechnology. In a recent study, the author developed an effective method to produce biologically 
active human Fas ligand extracellular domain derivatives using site-specific chemical modifications.
Findings: A human Fas ligand extracellular domain derivative containing a reactive cysteine residue within its 
N-terminal tag sequence, which locates not proximal to the binding interface between the ligand and the receptor 
in terms of the three-dimensional structure, was modified by Fluorescein-5-Maleimide without impairing the specific 
binding activity toward human Fas receptor extracellular domain. The purified protein sample free of low molecular-
weight contaminants showed a characteristic fluorescence spectrum derived from the attached Fluorescein moieties, 
and formed a stable binding complex with human Fas receptor extracellular domain—human IgG1 Fc domain fusion 
protein in solution. The conjugation number of the fluorochrome was estimated to be 2.5 per a single human Fas 
ligand extracellular domain trimer from the ratio of the absorbance value at 280 nm to that at 495 nm.
Conclusions: A functional fluorescent human Fas ligand extracellular domain derivative was prepared via a site-
specific conjugation of fluorochrome, which was guided by the three-dimensional structure information on the 
ligand-receptor complex. Fluorescent derivatives created by this method may contribute to the development of an 
improved diagnosis system for the diseases related to Fas receptor.
Keywords: Human Fas ligand, Extracellular domain, Fluorochrome, Site-specific conjugation, Three-dimensional 
structure, Receptor-binding activity
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Background
Fas ligand-induced apoptosis plays an essential role in 
maintaining human health, and loss of function of this 
system directly leads to the onset of serious diseases 
(Nagata 1999). Therefore, this protein has been consid-
ered as an important target for the therapy of diseases, 
especially cancers and immunologic disorders (Linker-
mann et al. 2005; Villa-Morales and Fernández-Piqueras 
2012). Accordingly, a number of engineered proteins 
concerning human Fas ligand (CD178) were devised for 
possible treatment of such diseases to date (Villa-Morales 
and Fernández-Piqueras 2012; Wajant et al. 2013). Also, 
the clinical significance of soluble form of the counter-
part receptor, human Fas receptor (CD95), as a poten-
tially useful diagnostic biomarker has been repeatedly 
pointed out in medical evaluation studies on a variety 
of cancers (Holdenrieder and Stieber 2004). The overall 
potential of human Fas ligand extracellular domain (hFa-
sLECD) for various applications in the field of medical 
biotechnology concerning therapeutic relevance, sample 
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preparation and structure–function relationships was 
summarized in a recent review paper (Muraki 2014a).
Chemical modification is a powerful methodology for 
creating artificially engineered proteins with novel, useful 
properties, which are not available in the original protein 
molecules (Chalker et al. 2011). On the other hand, con-
ducting the chemical modifications raises the possibility 
of impairment of valuable biological activity of the orig-
inal proteins, if randomly performed. In a recent study, 
the author developed a new method to introduce chemi-
cal modifications into an hFasLECD derivative via the 
conjugation of a reactive cysteine residue existing in the 
N-terminal tag sequence with a maleimide group con-
taining compounds (Muraki 2014b). The modifications 
were able to be carried out without damaging the original 
biological functions including apoptosis inducing activity 
of hFasLECD in the presence of a cross-linking antibody.
In the present study, the conjugation with a maleimide 
group containing derivative of one of the most popular 
fluorochromes in cell-biological researches, Fluorescein-
5-Maleimide (FL-5Mal), was examined as an extension 
of the above mentioned method to explore the possi-




hFasLECD containing single deletion mutation from 103 
to 138 and double substitution mutations (N184Q and 
N250Q) [hFasLECD (139-281, N184Q, N250Q)] with an 
N-terminal FLAG-(GlyCysGlyGlyGlyGly) tag sequence 
(NFG1CG4-hFasLECD) and that with an N-terminal 
FLAG-(Gly)5 tag sequence (NFG5-hFasLECD) were pre-
pared as described (Muraki 2008, 2014b). FL-5Mal was 
obtained from Tokyo Chemical Ind. Dimethyl Sulfox-
ide, Super Dehydrated (Dry DMSO), l-Cysteine hydro-
chloride monohydrate and pre-cast gels for SDS-PAGE 
analysis (Supersep Ace, 10–20  % gradient gels) were 
from Wako Pure Chemicals Ind. BCA protein assay kit 
and Tris-(2-carboxyethyl)phosphine (TCEP) neutral pH 
solution were purchased from Thermo Fisher Scientific. 
Ion-exchange chromatography and size-exclusion chro-
matography were performed using prepacked columns 
from GE healthcare. Ultracentrifugation devices for sam-
ple concentration [Amicon Ultra 4 and 15, molecular-
weight cut off (MWCO): 10  kDa] were supplied from 
Merck Millipore. Phosphate, acetate and Tris-hydrochlo-
ride buffers were the products of Nakarai Tesque (the 
former two) and Nippon Gene, respectively. SureBeads 
Protein A Magnetic Beads and washing buffer reagents 
used in immunoprecipitation experiments were from 
Bio-Rad Laboratories and Roche Diagnostics. Chemical 
structure of FL-5Mal was drawn using ChemBioDraw 
Ultra, ver. 14.
Reaction of NFG1CG4‑hFasLECD with FL‑5Mal
The recombinant NFG1CG4-hFasLECD was produced 
by a Pichia pastoris secretion system. The sample used 
for the modification with FL-5Mal was pre-purified by 
cation-exchange chromatography (Hi-Trap SP HP) pre-
ceding the conjugation reaction as described (Muraki 
2014b), and protein concentration of the purified sam-
ple was determined to be 7.6  mg/ml by a BCA protein 
assay kit using bovine serum albumin as a standard. The 
solution (1.5  ml) containing 11.4  mg protein was first 
mixed with 30  μl of 0.5  M Ethylenediaminetetracetic 
acid sodium salt (EDTA Na) solution (pH 8.0) and then 
treated with 30 μl of 0.5 M TCEP solution (neutral pH), 
which gave a final reaction mixture containing 10  mM 
each of EDTA Na and TCEP. The reaction mixture was 
incubated for 1 h at 297 K and subsequently subjected to 
a PD-10 size-exclusion chromatography column, which 
was pre-equilibrated and resolved using 25  mM phos-
phate buffer plus 2  mM EDTA Na (pH 6.4) as the elu-
ent. The elution fraction (3.5 ml) containing the reduced 
NFG1CG4-hFasLECD after removing the excess amount 
of TCEP was diluted with 6.2  ml of the same buffer. 
Then, freshly prepared 20 mM FL-5Mal solution in Dry 
DMSO (0.97  ml) was added, and incubated for 1  h at 
297  K to give a fluorescent deep-orange solution. After 
1 h, the excess FL-5Mal was quenched by adding 19 μl of 
1 M l-Cysteine hydrochloride, which immediately turned 
the color of the reaction mixture to deep-yellow show-
ing stronger fluorescence, and further incubated for 1 h 
at 297 K. During all the reaction time after the addition 
of FL-5Mal, a polypropylene vessel used in the reactions 
was wrapped with aluminum foil for shading from light 
as possible.
Purification of FL‑5Mal conjugated NFG1CG4‑hFasLECD
Purification of NFG1CG4-hFasLECD conjugated with 
FL-5Mal was conducted by three steps of size-exclusion 
chromatography. In the former two steps, a PD-10 col-
umn and 50  mM sodium acetate buffer (pH 5.5) were 
used as the chromatography device and the elution 
buffer in a gravity flow mode, respectively. In the first 
resolving step, a 2.5  ml each aliquot of the quenched 
conjugation reaction mixture was applied to the column 
and one ml each fraction was collected into the reser-
voirs. The early five fractions starting from the second 
fraction eluted as clear yellow solutions, which showed 
weaker fluorescence than the seventh and the following 
fractions emitting much stronger lemon-yellow fluores-
cence. Only the four elution fractions (from the second 
Page 3 of 9Muraki  SpringerPlus  (2016) 5:997 
to the fifth fraction) containing the conjugated pro-
tein were combined together (total volume 22  ml) and 
concentrated to approximately 4.0  ml using an Ami-
con Ultra 15 (MWCO: 10  kDa) device. Then, a 2.0  ml 
each aliquot was subjected to the second resolving step 
using a PD-10 column for the purpose of removing the 
low-molecular weight contaminants completely. At this 
stage, the yield of recovered protein was 5.3 mg in 7.0 ml 
solution. This sample was used for the final purifica-
tion step by high-performance size-exclusion chroma-
tography (used column: Superdex 200 10/300 GL, bed 
dimensions: 10 × 300 mm, bed volume: approximately 
24 ml). In this step, 50 mM Tris-hydrochloride contain-
ing 150 mM sodium chloride (pH 7.5) was employed as 
the elution buffer. The flow rate was set to 0.5  ml/min 
and a 230 μl each aliquot of the sample was applied to 
the column for an individual run. Two significant peaks 
at identical positions were detected by the measurement 
of absorbance at both 280 and 495  nm, and each peak 
fractions were collected independently. After concen-
tration using an Amicon Ultra 4 (or 15) centrifugation 
device (MWCO: 10  kDa), the collected samples were 
subjected to examine the content by a SDS-PAGE anal-
ysis. The same sample was also examined in the com-
plex formation experiments with human Fas receptor 
extracellular domain—human IgG1 Fc domain (hFasR-
ECD-Fc) using immunoprecipitaion and size-exclusion 
chromatography analyses.
Production and purification of hFasRECD‑Fc
The recombinant hFasRECD-Fc protein was produced in 
a baculovirus—Bombyx mori larvae expression system, 
and purified using an affinity chromatography column 
(Hi-Trap Protein G HP) and an anion-exchange chro-
matography column (Mono Q 10/10) as described in the 
previous paper (Muraki and Honda 2010).
Spectroscopic measurements
Ultraviolet–visible (UV–Vis) absorbance spectra were 
recorded on a Bio-Rad SmartSpec Plus Spectrophotom-
eter in the range from 250 to 600 nm using a two-sides 
clear quartz cuvette of 1 cm light-path length. A couple of 
absorbance values at 280 and 495 nm were also measured 
independently for the calculation of an estimated number 
of the conjugated FL-5Mal moieties to NFG1CG4-hFa-
sLECD. Fluorescence spectra were recorded on a KON-
TRON SFM25 spectrofluorometer under the conditions 
of the excitation wavelength at 495 nm and the emission 
wavelength scan range from 700 to 400 nm using a four-
sides clear quartz cuvette of 1  cm excitation light-path 
length. Protein samples of 0.125  mg/ml concentration 
in 50 mM Tris-hydrochloride buffer containing 150 mM 
sodium chloride (pH 7.5) were used for the measure-
ments at 298 K.
Estimation of the conjugation number
The number of FL-5Mal moieties conjugated to 
NFG1CG4-hFasLECD was estimated according to the 
calculation equations described in the instruction man-
ual of Pierce FITC Antibody Labeling kit (Thermo Fisher 
Scientific Inc. 2014) from the measured absorbance val-
ues at 280 and 495  nm. Molar extinction coefficient of 
Fluorescein group at 495 nm and that of NFG1CG4-hFa-
sLECD at 280  nm were assumed as 70,000 and 29,005, 
respectively. The latter value was obtained using the Prot 
Param tool on the ExPASy Server (Gasteiger et al. 2005).
Detection of the complex formation
Detection of the specific binding activity of the FL-5Mal 
conjugated NFG1CG4-hFasLECD samples (5.0  μg each) 
toward the hFasRECD-Fc sample (8.0 μg) was conducted 
using a Protein A conjugated magnetic beads (1.0  mg) 
by a receptor-mediated co-immunoprecipitation in 
50  mM Tris-hydrochloride buffer (pH 7.5) containing 
150  mM sodium chloride, 1  % Nonidet P40 and 0.5  % 
sodium deoxycholate (1.0 ml). The bound FL-5Mal con-
jugated NFG1CG4-FasLECD—hFasRECD-Fc complex 
on the beads was rigorously washed twice using the same 
buffer (1.0 ml). After the final washing with 10 mM Tris-
hydrochloride buffer (pH 7.5) containing 0.1  % Nonidet 
P40 and 0.05 % sodium deoxycholate (1.0 ml), the bound 
protein complex was solubilized using a non-reducing 
SDS-PAGE sample loading buffer (40  μl) composed of 
125  mM Tris-hydrochloride (pH 6.8), 4.3  % SDS, 30  % 
Glycerol and 0.01 % Bromophenol Blue dye by incubating 
at 343 K for 12 min.
Another experiment for the detection of complex 
formation between FL-5Mal conjugated NFG1CG4-
hFasLECD and hFasRECD-Fc was conducted by high-
performance size-exclusion chromatography. An initial 
attempt was performed by injecting a mixture of the 
Mono Q column purified hFasRECD-Fc sample (30  μg) 
and the PD-10 column purified FL-5Mal conjugated 
NFG1CG4-hFasLECD sample (22 μg). With regard to the 
more detailed examination using the main peak samples 
purified by a Superdex 200 column, the mixture solutions 
composed of hFasRECD-Fc (19.4 μg) and FL-5Mal con-
jugated NFG1CG4-hFasLECD (5.0, 7.5, 15 or 30  μg) in 
230 μl solution were analyzed. In all cases, the resolution 
by a Superdex 200 10/300 GL size-exclusion chroma-
tography column using 50  mM Tris-hydrochloride con-
taining 150 mM sodium chloride (pH 7.5) as the elution 
buffer under the flow rate of 0.5  ml/min was employed 
for the analyses.
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Results and discussion
Conjugation design
Recognition of death receptors by death ligands includ-
ing Fas ligand has been considered as important tar-
gets for therapy of many serious human diseases such 
as cancers (Ashkenazi 2008; Russo et  al. 2010), and the 
specific interaction between the extracellular domains 
of them is a fundamental to the recognition. The extra-
cellular domains of the proteins belonging to death 
ligands and death receptors, also called as tumor necro-
sis factor (TNF) ligand superfamily and TNF receptor 
superfamily, share each common structural features in 
three-dimensions (Bodmer et  al. 2002). To date, several 
detailed three-dimensional structures of the extracellu-
lar domain complexes, including human TNF receptor–
human TNFβ complex (Banner et  al. 1993) and human 
death receptor 5–human TNF related apoptosis inducing 
ligand complex (Hymowitz et  al. 1999), have been elu-
cidated by mean of crystallography. A typical structure 
of the extracellular domain complexes is composed of 
three monomers of the receptor’s extracellular domains 
and one trimer of the ligand’s extracellular domains. 
Although no three-dimensional structure of the extra-
cellular domains complex between human Fas ligand 
and human Fas receptor itself has been experimentally 
disclosed yet, a detailed three-dimensional structure of 
the extracellular domains complex between human Fas 
ligand and human decoy receptor 3 (hDcR3), which was 
revealed by X-ray crystallography, is already available 
(Liu et  al. 2013). This X-ray structural model provided 
important information for the design of the conjugation 
site in this study. Although the primary sequence identity 
between hFasR and hDcR3 is moderate (17 %, Pitti et al. 
1998), the three-dimensional interaction modes with 
hFasLECD, forming the binding interfaces of the ligand-
receptor complexes, are considered essentially conserved 
to each other (Whalen and Hymowitz 2014).
Figure  1 presents the three-dimensional structure 
of the hFasLECD–hDcR3 complex (Liu et  al. 2013). It 
was aimed to create a functional hFasLECD derivative 
containing Fluorescein residue in this study. Probably, 
the most popular strategy for introducing Fluorescein 
moieties into protein molecules, such as antibodies, 
is to modify the lysine residues present on the surface 
of the proteins by Fluorescein isothiocyanate (Thermo 
Fisher Scientific Inc. 2014). However, each NFG1CG4-
hFasLECD monomer contains fourteen lysine residues 
including the two residues within the N-terminal FLAG 
tag sequence, and most of them locate on the molecu-
lar surface of the protein (Additional file 1). These lysine 
residues are often conserved among other animals’ Fas 
ligand extracellular domains (Motegi-Ishiyama et  al. 
2001). So far, two of them are suggested to be critical for 
the specific binding toward hFasRECD due to the exist-
ence of the residues at the binding interface. The side 
chain group of Lys 228 was predicted to form a salt-
bridge with that of Asp 92 in hFasRECD from a molecu-
lar modeling study (Bajorath 1999). Lys 217 also locates 
in the contact site and is neighboring to Tyr 218, which 
was suggested to play an important role in the binding 
interactions from a mutagenesis study (Schneider et  al. 
1997). Therefore, a random modification of the lysine res-
idues with fluorochrome moieties can significantly dam-
age the receptor binding activity.
In contrast, only one unpaired cysteine residue in 
the N-terminal tag region and a single pair of disulfide-
bridged cysteine residues within the folded region exist 
in NFG1CG4-hFasLECD. Judging from the position of 
the N-terminal residue (Leu143) in the three-dimen-
sional structure of the hFasLECD–hDcR3 complex 
(Fig. 1) as well as from the fairly hydrophilic property of 
the N-terminal FLAG tag plus aa 139-142 region (Asp–
Tyr–Lys–Asp–Asp–Asp–Asp–Lys–Gly–Cys–Gly–Gly–
Gly–Gly–Glu–Lys–Lys–Glu), the unpaired Cys was 
expected to locate not proximal to the binding interface, 
but exposed to the solvent in an aqueous solution of neu-
tral pH. Although the pre-activation by a treatment with 
some reducing agents was necessary for an efficient con-
jugation because of the propensity to form a disulfide-
bridge between two NFG1CG4-hFasLECD monomer 
subunits due to non-specific oxidation of the unpaired 
cysteine residue, it was demonstrated that selective 
activation of the conjugation site alone was possible by 
choosing the mild reducing condition using TCEP for the 
reaction in the previous study (Muraki 2014b). Moreo-
ver, the resulting conjugates with several kinds of single 
or double maleimide group(s) containing compounds 
maintained the receptor binding activity, and also one 
conjugate was proved to exhibit significant cytotoxic 
activity against a cancer cell line after cross-linking by an 
anti-FLAG tag antibody (Muraki 2014b). Consequently, 
FL-5Mal was chosen as the modification reagent for the 
conjugation in this study.
Preparation and characterization of FL‑5Mal conjugated 
NFG1CG4‑hFasLECD
The conjugation procedures used in this study are sum-
marized in Fig. 2a. In Fig. 2b, SDS-PAGE analysis of the 
reaction mixtures at each step (lanes 1–3) and the early 
six fractions in the first purification step using size-
exclusion chromatography (lanes 4–9) are presented. The 
purified sample after a complete removal of low-molec-
ular weight contaminants by the second size-exclusion 
chromatography still contained impurities shown as 
some minor bands less than 20.1 kDa and a sharp band 
between the size markers of 66.3 and 97.4 kDa arrowed 
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in Fig. 2b. Judging from the band position, the latter com-
ponent was considered to be the host-derived alcohol 
oxidase 1 (AOX-1) (molecular weight under the denatur-
ing conditions: 75  kDa) (Zhang et  al. 2009), which was 
co-purified from the culture medium used for the secre-
tory production of NFG1CG4-hFasLECD in P. pastoris 
(Muraki 2014b).
Figure  3a presents the high-performance size-exclu-
sion chromatography profiles for the partially purified 
samples of FL-5Mal conjugated NFG1CG4-hFasLECD 
and hFasRECD-Fc, and a mixture of them. The conju-
gated NFG1CG4-hFasLECD sample after the second 
size-exclusion chromatography using a gravity flow col-
umn showed one major peak eluted at 28.61  min (peak 
2) and a small preceding peak at 24.70  min (peak 1) 
(Fig.  3a, top panel) with respect to the absorbance at 
both 280 and 495 nm. The hFasRECD-Fc sample after the 
anion-exchange chromatography purification showed a 
main peak at 23.32  min presenting only the absorbance 
at 280  nm (Fig.  3a, middle panel). The mixture sample 
showed a main peak at an earlier position (22.36  min) 
than the receptor alone sample with regard to the absorb-
ance at both 280 and 495  nm (Fig.  3a, bottom panel), 
indicating a stable complex formation derived from the 
strong interactions between them. The two independ-
ent peak fractions regarding the FL-5Mal conjugated 
NFG1CG4-hFasLECD sample, the main peak fraction 
concerning the hFasRECD-Fc sample and that of the 
mixture sample were collected and the components were 
analyzed by SDS-PAGE (Fig.  3b, lanes 2–5). In addi-
tion, the two peak fractions of the FL-5Mal conjugated 
NFG1CG4-hFasLECD sample were also examined by a 
receptor-mediated co-immunoprecipitaion experiment 
(Fig. 3b, lanes 6–9). The peak 2 sample showed an almost 
uniform molecular weight slightly larger than NFG5-hFa-
sLECD (Fig.  3b, lane 1) due to the addition of FL-5Mal 
Fig. 1 Three-dimensional structure of hFasLECD–hDcR3 complex. The atomic coordinate data were obtained from PDB (ID: 4msv). A biological unit 
image composed of a single hFasLECD trimer (aa 143–281, yellow) and a triply bound hDcR3 monomers (aa 33–193, white) is presented as a space-
filling model. The N-terminal residue in this model (Leu 143), the two lysine residues mentioned in the text (Lys 218 and Lys 228) and the other 
lysine residues are shown in green, red and cyan, respectively. a A vertical view, b a vertical view (after 180 degree rotation of a), c a horizontal view, d a 
horizontal view (after 180 degree rotation of c)
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Fig. 2 Conjugation of FL-5Mal to NFG1CG4-hFasLECD. a Experimental procedures. b SDS-PAGE analysis of the conjugation reaction and resolution 
by the first size-exclusion chromatography. Lanes: M molecular-weight size markers (14.4, 20.1, 30.0, 42.4, 66.3 and 97.4 kDa), 1 TCEP reduced sample 
before conjugation reaction, 2 after conjugation reaction, 3 after quenching reaction, 4 initial flow-through fraction (2.5 ml) in the first size-exclusion 
chromatography, 5–9 following fractions (1 ml each). Used column, PD-10. Thick and thin arrows indicate the positions of FL-5Mal conjugated hFa-
sLECD and P. pastoris AOX-1, respectively
Fig. 3 Purification using high-performance size-exclusion chromatography. a Elution profiles of the partially purified samples and a mixture of 
them. Top panel FL-5Mal conjugated NFG1CG4-hFasLECD; Middle panel hFasRECD-Fc; Bottom panel the mixture. Used column, Superdex 200 10/300 
GL. Elution buffer, 50 mM Tris-hydrochloride plus 150 mM sodium chloride (pH 7.5). Absorbance at 280 nm (blue) and 495 nm (red) was used for the 
detection. Flow rate, 0.5 ml/min. The retention time of each peak position is shown. The regions shown in underbars were collected and used for 
the analysis in b. b SDS-PAGE analysis of the purified samples. Lanes: M molecular-weight size markers (14.4, 20.1, 30.0, 42.4, 66.3 and 97.4 kDa), 1–5 
purified samples (1, NFG5-hFasLECD; 2 and 3 peak 2 and peak 1 of the FL-5Mal conjugated NFG1CG4-hFasLECD sample, respectively, 4 main peak of 
the hFasRECD-Fc sample, 5 main peak of the mixture sample), 6–11 receptor-mediated co-immunoprecipitation (6 and 8 purified proteins, 10 buffer 
only, 7, 9 and 11 co-immunoprecipitated materials; 6 and 7 peak 2 of the FL-5Mal conjugated NFG1CG4-hFasLECD sample, 8 and 9 peak 1 of the FL-
5Mal conjugated NFG1CG4-hFasLECD sample, 10 and 11 the buffer only sample). Thick and thin arrows indicate the positions of FL-5Mal conjugated 
hFasLECD and hFasRECD-Fc, respectively
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moiety and no longer contained the AOX-1 impurity 
(Fig.  3b, lanes 2 and 6), which was still observed in the 
sample after the second gravity flow size-exclusion chro-
matography purification. This sample precipitated with 
Protein A conjugated magnetic beads in the presence of 
hFasRECD-Fc, confirming the specific binding activity of 
the hFasLECD conjugate to the hFasRECD-Fc (Fig.  3b, 
lane 7). The peak 1 sample was a mixture of mainly 
three components, showing discrete molecular-weights 
(Fig.  3b, lanes 3 and 8). Interestingly, only the aster-
isked component showing the highest molecular-weight 
did not co-precipitated with the hFasRECD-Fc (Fig.  3b, 
lane 9). The main peak fraction obtained from the mix-
ture sample contained both the ligand and the receptor 
components (Fig.  3b, lane 5). Under the same resolving 
conditions, molecular-weight standard samples of Thy-
rogloblin (669 kDa), Aldolase (158 kDa) and Ovalbumin 
(43 kDa) showed the peak retention time of 17.56, 24.28 
and 29.20  min, respectively (Additional file  2). Purifica-
tion of the FL-5Mal conjugated NFG1CG4-hFasLECD 
sample using a cation-exchange chromatography was not 
effective because of the broadening of the peak concomi-
tant with a significant retardation probably due to the 
attached hydrophobic Fluorescein moieties (Additional 
file 3).
The main peak sample of FL-5Mal conjugated 
NFG1CG4-hFasLECD purified by high-performance 
size-exclusion chromatography was then character-
ized using a couple of spectroscopic analyses. As shown 
in Fig. 4a, the sample presented two major peaks at 280 
and 495 nm, which can be attributed to mainly from the 
protein part and the conjugated Fluorescein group, in 
the UV–Vis spectrum, respectively. From the ratio of the 
absorbance value at 280 nm to that at 495 nm, the conju-
gation number of FL-5Mal per a single NFG1CG4-hFa-
sLECD trimer was estimated to be 2.5.
This result indicated that approximately 83  % of the 
unpaired cysteine residues in the NFG1CG4-hFasLECD 
sample were modified by the FL-5Mal molecules, since 
each single monomer constituting the trimer has one 
conjugation site within its N-terminal tag sequence. On 
the other hand, the measurement using a spectrofluo-
rometer excited at 495  nm presented the characteristic 
emission spectrum derived from a Fluorescein moiety 
(BD Bioscience 2016) showing an intense yellow–green 
fluorescence with the maximum wavelength at 520  nm 
(Fig. 4b).
Finally, the complex formation of FL-5Mal conjugated 
NFG1CG4-hFasLECD with hFasRECD-Fc was further 
examined more in detail by altering the relative mixing 
ratio of the main peak samples purified by the high-per-
formance size-exclusion chromatography (Fig.  5, panels 
a–d). The 495  nm absorbance observed only with FL-
5Mal conjugated NFG1CG4-hFasLECD was helpful in 
monitoring the elution position of this component. By 
gradually increasing the amount of FL-5Mal conjugated 
NFG1CG4-hFasLECD under the fixed amount of hFasR-
ECD-Fc in the sample mixture, the 495 nm peak showing 
constant elution time (22.74  min) corresponding to the 
formed complex first became higher (panels a and b) and 
then the peak of the left over ligand component after sat-
uration appeared at 28.02 min or 28.50 min (panels c and 
d). This phenomenon suggested that the peak fraction 
eluted at 22.74 min was consisted of the complex formed 
from a limited number of the ligand component and the 
receptor component.
Conclusions and implications
In conclusion, it was possible to prepare a fluorescent 
derivative of hFasLECD using a site-specific chemical 
conjugation of FL-5Mal to NFG1CG4-hFasLECD with-
out impairing the specific hFasRECD binding activity. 
Fig. 4 Spectroscopic analysis of FL-5Mal conjugated NFG1CG4-hFasLECD. The purified peak 2 sample of the FL-5Mal conjugated NFG1CG4-
hFasLECD was used. a UV–Vis spectrum (250–600 nm). b Fluorescence emission spectrum (400–700 nm) excited at 495 nm. Insert a fluorescence 
emission observed in the measurement cuvette
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This method will be readily applicable to other fluoro-
chromes, if the corresponding maleimide derivatives 
are available. Fluorescent derivatives of ligand proteins 
and antibodies are useful for immunofluorescence imag-
ing studies as well as flow cytometry analyses targeted 
to their counterpart receptors, especially those on the 
surface of viable cells (Schechter et al. 1978; Sako et al. 
2000; Urano et  al. 2009). It was suggested that many 
clinically relevant cytotoxic drugs such as cisplatin alter 
the susceptibility of a variety of tumor cells to apopto-
sis through the enhanced expression (Micheau et  al. 
1997; Galenkamp et al. 2015) and the clustering in lipid 
rafts (Lacour et  al. 2004; Lim and Han 2015) of the 
cell-surface Fas receptor. The fluorescent derivative of 
functional hFasLECD created by the method described 
in this paper may contribute to the development of an 
improved diagnostic system as a new additional molecu-
lar tool accompanied by treatments of the disorders, in 
which the states of Fas receptor are reflected by the dis-
eases’ conditions.
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